patented drugs

Printer-friendly version
Ottawa’s revisions to drug-pricing review board will delay or prevent access to new drugs

Pharmaceutical manufacturers take on a significant investment risk to develop new drugs.

Printer-friendly version
The opposition of the two U.S. presidential candidates to the Trans-Pacific Partnership (TPP) threatens progress on trade issues including intellectual property protection.